Abeona Therapeutics (LTS:0H7R) LT-Debt-to-Total-Asset : 0.15 (As of Sep. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Abeona Therapeutics LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Abeona Therapeutics's long-term debt to total assests ratio for the quarter that ended in Sep. 2024 was 0.15.

Abeona Therapeutics's long-term debt to total assets ratio increased from Sep. 2023 (0.06) to Sep. 2024 (0.15). It may suggest that Abeona Therapeutics is progressively becoming more dependent on debt to grow their business.

Abeona Therapeutics LT-Debt-to-Total-Asset Historical Data

The historical data trend for Abeona Therapeutics's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Abeona Therapeutics LT-Debt-to-Total-Asset Chart

Abeona Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.03

0.04

0.10

0.09

0.07

Abeona Therapeutics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.06	0.07	0.30	0.14	0.15

Abeona Therapeutics LT-Debt-to-Total-Asset Calculation

Abeona Therapeutics's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )	/	Total Assets (A: Dec. 2023 )
	=	4.402	/	64.002
	=	0.07

Abeona Therapeutics's Long-Term Debt to Total Asset Ratio for the quarter that ended in Sep. 2024 is calculated as

LT Debt to Total Assets (Q: Sep. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Sep. 2024 )	/	Total Assets (Q: Sep. 2024 )
	=	17.608	/	120.592
	=

Abeona Therapeutics (LTS:0H7R) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Abeona Therapeutics LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Abeona Therapeutics's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Abeona Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Abeona Therapeutics Inc (LTS:0H7R) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

ABEO:USA PCJ:Germany PCJ:Germany

Address

6555 Carnegie Avenue, 4th Floor, Cleveland, OH, USA, 44103

Website

https://www.abeonatherapeutics.com

Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel AIM.

Abeona Therapeutics Headlines

No Headlines